Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03598998CT.gov Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | — | Active Not Recruiting | — | — | — |
NCT01336933CT.gov Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatosplenic T-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pralatrexate (this asset) | City of Hope Medical Center | P2 | BB · 64 |
| Isocyclophosphamide | Shandong Provincial Hospital | P4 | BBB |
| Fludarabine | National Cancer Institute (NCI) | P2 | BBB |
| Adriamycin | National Cancer Institute (NCI) | P4 | BBB |
| Prednisone | City of Hope Medical Center | P4 | BBB |
| Etoposide | City of Hope Medical Center | P4 | BBB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BBB |
| Lenalidomide | University of Nebraska | P2 | BB |
| Dexasone | University of Nebraska | P2 | BB |
+42 more in the Hepatosplenic T-Cell Lymphoma cohort
Other indications for Pralatrexate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 74 |
| Angioimmunoblastic T-Cell Lymphoma | — | P3 | BB · 66 |
| Nodal T-Follicular Helper Cell Lymphoma, Follicular Type | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pralatrexate in Hepatosplenic T-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pralatrexate-hepatosplenic-t-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →